Materials and Methods

Steroids
MTS, MSL, NAD, and STZ were obtained from SigmaAldrich Japan (Tokyo, Japan); MDI, from Gedeon Richter (Budapest, Hungary); MDO, from Diosynth (Oss, The Netherlands); OXM, from Edmond Pharma (Paderno Dugnano, MI, Italy); BLD and MNL, from Steraloids (Newport, RI); FOM, from Kanto Kagaku Reagent Division (Tokyo, Japan); and Deca Duramin ® (NAD decanoate), from Fuji Pharmaceutical (Tokyo, Japan). 5a-Estran-3b,17a-diol, the main metabolite of NAD, was obtained from Steraloids. 16a-Hydroxyfurazabol was synthesized in our laboratory according to a report of Takegoshi et al. 7 16a-Hydroxystanozolol and 16b-hydroxystanozolol were synthesized in our laboratory according to a report of Schänzer et al. 12 17a-Methyl-5a-androstan3b,16b,17b-triol, a metabolite common to MTS, MSL, MDO, MDI, and OXM, and 17a-methyl-5b-androstan-3a,16b,17b-triol, a metabolite common to MDO, MDI, and MTS, were synthesized in our laboratory according to our previous report. 1 9a-Fluoro-17,17-dimethyl-19-norandrostane-4,13-diene-11b-ol-3-one, the main metabolite of FOM, was synthesized in our laboratory according to our previous report.
3 [16, 16, H3]-5a-Androstane-3a,17b-diol ( 2 H3-AND), which was used as an internal standard (IS), was synthesized in our laboratory according to a report of Dehennin et al. 13 Chemicals and reagents N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) was purchased from GL Sciences (Tokyo, Japan). A Sep-Pak Plus C18 360 mg/cartridge (Nihon Waters, Tokyo, Japan) was used as an SPE column, and a 1 M hydrogen chloride-methanol solution was obtained from Kokusan Kagaku (Tokyo, Japan 
Urine samples
We used the urine samples of post-race female or gelding thoroughbreds submitted for routine doping tests as authentic urine samples. In order to obtain urine samples after NAD administration, we used three male experimental thoroughbreds housed at the Equine Research Institute, Japan Racing Association. NAD decanoate was administered intramuscularly to each horse at 0.8 mg/kg. Urine samples were collected prior to NAD decanoate administration, and post NAD decanoate administration from each horse, and stored at temperatures below -40˚C prior to analysis. All experimental procedures in this study were approved by the Animal Care Committee of the Equine Research Institute, Japan Racing Association.
Selection of target substances
Regarding the target substance for the doping test, we selected known main metabolites that were detected after anabolic steroid use. The structures of the parent steroids and the target substances are shown in Fig. 1 .
Boldenone (BLD), methenolone (MNL).
According to Dumasia et al., the parent steroid, itself, and the 17-epimer of sulfate and glucuronide conjugates were detected as main urinary metabolites of BLD in horse. 4, 5 On the other hand, the urinary metabolites of MNL in horse were reported by Yu et al.; namely, 17-epi-methenolone and the parent steroid were detected as glucuronide conjugates. 6 Therefore, the target substances for simultaneous analysis used to determine BLD and MNL abuse were the parent steroids, themselves, because the acquisition of authentic reference standards is easy.
Fluoxymesterone (FOM).
Prior to this study, we investigated FOM metabolism, and confirmed that 9a-fluoro-17,17-dimethyl-19-norandrostane-4,13-diene-11b-ol-3-one (FDN) was the main metabolite of FOM in horse urine, the same as in humans. 3 A small amount of the parent steroid was detected in horse urine after FOM administration. Therefore, the target substances for simultaneous analysis to determine FOM abuse were FOM and FDN.
Furazabol (FRZ), stanozolol (STZ).
The main metabolite of FRZ in rat or human was reported to be the 16-hydroxylated product of FRZ by Takegoshi et al. and Gradeen et al. 7, 8 However, there is no report on the main metabolites in horse. On the other hand, McKinney et al. reported that the main urinary metabolite of STZ in horse is the 16-hydroxylated product of STZ. 9 We synthesized reference standards of 16a-hydroxyfurazabol, 16a-hydroxystanozolol, and 16b-hydroxystanozolol, and identified each metabolite in our laboratory, but did not publish the results. As results, the main metabolites of FRZ and STZ were 16a-hydroxyfurazabol (HFR) and 16a-hydroxystanozolol (HST), respectively. In addition, small amounts of the parent steroids were detected. Therefore, FRZ, HFR, STZ, and HST were selected as target substances. 1, 2 and confirmed that 17a-methyl-5a-androstan-3b,17b-diol, 17a-hydroxymethyl-5a-androstan-3b,17b-diol, 17a-methyl-5a-androstan-3b,16a,17b-triol, and 17a-methyl-5a-androstan-3b,16b,17b-triol (MAT) were metabolites common to the five steroids. Further, the 5b-H structural metabolite 17a-methyl-5b-androstan-3a,16b,17b-triol (5bMAT) was detected in the urine of MDI-, MDO-, or MTSadministered horses, but not in MSL-or OXM-administered ones. In addition, small amounts of the parent steroids were detected in horse urine after MTS, MDO, and MDI administration. MSL was detected in the urine of OXMadministered horse despite the fact that it was hardly detected in the urine of MSL-administered horse. Among the metabolites mentioned above, we have reported that MAT is a useful screening target for a doping test of the five steroids in racehorses, and we selected it as the target substance for simultaneous analysis to determine MDI, MDO, MTS, MSL, or OXM abuse. In addition, MDI, MDO, MTS, MSL, and 5bMAT were included as target substances, because these would help us to narrow down the candidate administered steroid.
Nandrolone (NAD).
Urinary metabolites of NAD were investigated in detail by Houghton and Teale, who reported that NAD was mainly excreted as 5a-estran-3b,17a-diol (ETA) sulfate and glucuronide in horse urine. 10, 11 Therefore, ETA, the urinary main metabolite of NAD, was selected as the target substance in the simultaneous analysis to determine NAD abuse.
Sample preparation
Urine (3 mL) was adjusted to pH 5.0 with 1 M acetate buffer (4.0 mL) and 2 H3-AND (500 ng) was added as IS. The mixture -dimethyl-18-norandrostane-4,13-dien-11b-ol-3-one; FRZ, furazabol; HFR, 16a-hydroxyfurazabol; STZ, stanozolol; HST, 16a-hydroxystanozolol; MDI, methandienone; MDO, methandriol; MTS, 17a-methyltestosterone; MSL, mestanolone; OXM, oxymetholone; MAT, 17a-methyl-5a-androstan3b,16b,17b-triol; 5bMAT, 17a-methyl-5b-androstan-3a,16b,17b-triol; NAD, nandrolone; ETA, 5a-estran-3b,17a-diol; 2 H3-AND, [16, 16, H3]-5a-androstane-3a,17b-diol.
was centrifuged at 1663g (radius of gyration, 16.5 cm; rpm, 3000) for 10 min, and loaded onto a Sep-Pak Plus C18 cartridge (pretreated with 5 mL of methanol and 5 mL of deionized water). The cartridge was rinsed with 5 mL of deionized water and 5 mL of n-hexane. Then, the cartridge was dried under a vacuum and eluted with 5 mL of ethyl acetate/methanol (5:1). The eluate was evaporated under nitrogen at temperatures below 40˚C and the residue was dissolved in a 1 M anhydrous hydrogen chloride-methanol solution (0.5 mL) and incubated for 10 min at 60˚C. Then, the residue was dissolved in diethyl ether (5 mL). Next, the solution was washed with 1.0 M sodium hydroxide and 0.15 M sodium chloride in water (2 mL). The solvents were evaporated under nitrogen at temperatures below 40˚C. After evaporation, the residue was dissolved in 50 mL of NH4I/dithioerythritol/MSTFA (2 mg/4 mg/1 mL), and the reaction was allowed to proceed at 80˚C for 30 min. Finally, 2 mL of this solution was injected into GC/MS/MS.
GC/MS/MS analysis
GC/MS/MS was performed on a gas chromatograph coupled with a GCQ ion-trap mass spectrometer and equipped with an A200S GC auto-sampler (Finnigan Thermo, CA). The fusedsilica capillary column used was DB-5ms (J & W Scientific, CA), having 15 m ¥ 0.25 mm i.d. and 0.25 mm film thickness. Helium was used as the carrier gas (50 cm/s), and the column oven temperature was programmed to increase from 150 to 320˚C at 15˚C/min, and maintained at 320˚C for 1 min. The injector temperature was set at 250˚C and the MS transfer line temperature at 275˚C. The collision energy was 1.0 eV and the excitation energy (qz value) was 0.225 for all GC/MS/MS analyses.
Results and Discussion
Study of a simultaneous analysis method
Target substances exist in unconjugated free, glucuronide, and sulfate forms in horse urine, and therefore conjugate decomposition should be performed prior to simultaneous analysis of the target substances. Although enzyme hydrolysis is generally used, this method is not applicable to some anabolic steroids conjugated with sulfate. The decomposition of sulfates or glucuronides with methanolysis using anhydrous hydrogen chloride-methanol has been reported. 14 Regarding derivatives of anabolic steroids and their metabolites, Stanley et al. reported the use of a mixed reagent of NH4I, dithioerythritol, and MSTFA, and obtained good results. 15 We adopted the mixed reagent for derivatives of target substances in this study. As a result, single trimethylsilylation products containing the keto or amino group were obtained, which enabled simultaneous analysis with high sensitivity and stability of most of the target substances.
In our simultaneous analysis, we employed GC/MS/MS, which has high sensitivity and specificity. The simultaneous analysis of GC/MS/MS analysis is attained by changing the precursor ion according to the retention time of the target substance. Prior to GC/MS/MS analysis, GC/MS full-scan data of the target compound were obtained with GCQ, and the precursor ion of GC/MS/MS was selected based on the obtained mass spectrum data. The retention times, full-scan data, and the selected precursor ions with the target substances are given in Table 1 . Although the molecular ion was selected as a precursor ion for most of the target substances, when the relative intensity of the molecular ion was weak, and sufficient sensitivity could not be obtained, the quasi-molecular ion was chosen. Typical selected product-ion chromatograms of the target substances from GC/MS/MS analysis are shown in Fig. 2 , and their product ion spectra are shown in Fig. 3 . The peak of each target substance was able to separate clearly in the product-ion chromatogram.
Method validation Sensitivity. The limit of detection (LOD) in this simultaneous
analysis is the minimum concentration that met the minimum criteria for identification provided by the Association of Official Racing Chemists. 16 The criteria include the following: the retention time of the test sample is in agreement with that of the reference standard; the relative abundance (RA) of more than three characteristic ions is within the tolerance level; all ions appearing in the reference standard mass spectrum with an RA greater than 10% must also be present in the test sample mass spectrum; and any extraneous ions present should not exceed 20% RA. As shown in Table 2 , LOD of the target substances was 5 -50 ng/mL. Among the anabolic steroids investigated in this study, BLD is listed for performance specification in laboratories for doping control required by International Federation of Horseracing Authorities (IFHA), and the minimum urinary concentration for detecting exposure is 20 ng/mL in horse. In the simultaneous analysis employed in this study, LOD of BLD was lower than that specified by IFHA. Specificity and reproducibility. To evaluate the specificity and reproducibility, the above-described method was assessed using different authentic urine samples and spiked urine samples with all of the target substances at the LOD concentrations listed in Table 2 . Each urine sample was examined by replicate analysis (n = 10) on three different days. As a result, all control urine samples gave negative results, while all of the spiked urine samples were positive. Extraction recovery. The absolute mean recovery and the coefficient of variation (CV) for the target substances and the IS are given in Table 2 . The recovery rates exceeded 70%, and CV was less than 10% for all of the target substances.
Nandrolone testing and application of method to administered samples
It is known that NAD is generated in the biosynthesis of estradiol from testosterone in male horse. 10, 11 Thus, its endogenous metabolites, which are not derived from NAD administration, are also excreted in urine. For this reason, NAD doping control in male horses has been conducted based on the threshold, namely, the concentration ratio of ETA to 5(10)-estren-3b,17a-diol (ETE), an endogenous substance that is not derived from NAD administration. The threshold, ETA/ETE = 1/1, is based on statistics of authentic horses provided by IFHA. Therefore, ETA, the urinary main metabolite of NAD, was selected as the target substance in a simultaneous analysis to determine NAD abuse. Although ETE was not selected as the target substance in this simultaneous analysis, when ETA is detected in male horse, it is necessary to confirm the ETA/ETE concentration ratio according to IFHA's ETA/ETE threshold.
For applying the method to administered samples, we administered NAD decanoate to male experimental thoroughbreds, and the collected urine was used for simultaneous analysis. The mass chromatogram and the product ion spectrum of urine sampled day 23 after NAD decanoate administration are shown in Fig. 4 .
The urine in this investigation was used to measure the concentration ratio of ETA/ETE already obtained in a previous study; namely, urine samples from day 1 or 2 to day 23 after administration had ETA/ETE ≥1/1.
17 Although ETA should be detected from the urine greater than a threshold, this simultaneous analysis method was able to well detect ETA in these urine samples.
In human sports, although NAD and testosterone are prohibited, and a threshold has been adopted for their detection, measuring the d 13 C value of the endogenous substance by gas chromatography/combustion/carbon isotope ratio mass spectrometry (GC/C/IRMS) is also recommended by World Anti-Doping Agency (WADA). 18 On the other hand, we investigated the applicability of GC/C/IRMS to the NAD doping test in racehorse, and found that the measurement of d 13 Mean ± CV (%), n = 7. with GC/C/IRMS enabled us to discriminate exogenous ETA derived from NAD-administered horse from endogenous ETA. 17 Since there are reports of complex metabolic disorders in humans, 19, 20 the possibility of such disorders occurring in racehorses cannot be completely denied. Thus, GC/C/IRMS is a useful technique to complement the ETA/ETE concentration ratio in confirming NAD doping in racehorses.
C values
17a-Methyltestosterone, mestanolone, methandienone, methandriol, and oxymetholone testing
Aside from MAT, we selected MTS, MDI, MDO, MSL, and 5bMAT as target substances to determine MTS, MSL, MDI, MDO, and OXM doping in the confirmatory analysis. We did this because MAT is common to the above five anabolic steroids, and selected target substances would narrow down the candidate administered steroids. The detection results of these five steroids after administration are given in Table 3 . It should be noted, however, that the metabolism of anabolic steroids is often dependent on the route of administration, and the metabolism of prodrugs may differ from the metabolism of their active forms. Therefore, identification of the abused drug should be conducted with care.
Conclusion
We examined a method for the simultaneous analysis of 15 kinds of metabolites from 11 anabolic steroids (BLD, FOM, FRZ, MDI, MDO, MNL, MTS, MSL, NAD, OXM, and STZ) for its possible application to a doping test for racehorses. Since the use of anabolic steroids should be strictly regulated in racehorses, we adopted GC/MS/MS for the simultaneous analysis, which has high sensitivity and specificity. Although methods for the simultaneous analysis of the parent steroids of the above-mentioned anabolic steroids have been reported, as far as we know, no method for the simultaneous analysis of the main urinary metabolites of the 11 anabolic steroids in horses has been reported. Therefore, our present findings are expected to contribute to improving the analysis of metabolites of anabolic steroids. This simultaneous analysis may have potential use for metabolites other than those in this study, and the results would contribute to an improvement of anabolic steroid analysis in racehorses.
